LifeVantage Corporation filings document formal disclosures for a Nasdaq-listed health and wellness company that sells nutrigenomic supplements, skin and hair care products, energy drink mixes, and pet supplements through an independent Consultant model. Recent Form 8-K reports furnish quarterly operating results and describe revenue by region, earnings measures, capital allocation, and material corporate events.
Proxy and meeting filings cover board elections, advisory executive compensation votes, auditor ratification, incentive-plan matters, and final stockholder voting results. Other current reports address executive departures, officer appointments, board changes, transition agreements, and compensatory arrangements, alongside exhibit-based press releases tied to financial results and governance actions.
Lifevantage Corporation (LFVN) held its annual stockholders meeting on November 5, 2026. Stockholders elected all six director nominees, approved named executive officer compensation on an advisory, non-binding basis, and ratified Deloitte & Touche, LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2027.
Lifevantage Corp. director Michael A. Beindorff reported a proposed sale of 10,000 common shares from an account titled Michael A. Beindorff Trust. The approximate sale date is November 12, 2026, and the shares have an aggregate market value of $47,200; Charles Schwab & Co. is named as broker. The listed number of common shares outstanding is 12,682,221.
Lifevantage Corp director Michael A. Beindorff received 17,888 common shares on November 5, 2026, under the outside director compensation program. The award vests in one installment on November 5, 2027, subject to his continuous service through that date. His direct holdings after the award were 45,458 shares; reported indirect holdings included 41,625 shares held by the Michael A. Beindorff Trust U/A DTD 06/14/2000, 126 held by his spouse as custodian for minor children, and 5,500 held by his spouse. The reported $5.87 per-share figure is the weighted average closing price for the ten trading days ending the day before the grant.
Lifevantage Corp director Rajendran Anbalagan acquired 17,888 common shares on November 5, 2026, under the issuer’s outside director compensation program. The award will vest in a single installment on November 5, 2027, subject to his continuous service through that date. The reported $5.87 per-share figure equals the weighted average closing price over the ten trading days ending the day before the grant; it is not described as a purchase price. He directly held 41,887 common shares following the grant.
Lifevantage Corp director Darwin Lewis received a grant of 17,888 common shares on November 5, 2026, under the company’s outside director compensation program. The shares will vest in a single installment on November 5, 2027, subject to his continuous service through that date. The reported $5.87 per share is the weighted average closing price for the ten trading days ending the day before the grant. Lewis reported direct holdings of 156,132 shares following the grant.
Lifevantage Corp (LFVN) director Raymond B. Greer received an award of 17,888 common shares on November 5, 2026. His reported direct holdings after the award were 130,707 shares. The award was made under the issuer’s outside director compensation program and is scheduled to vest in one installment on November 5, 2027, subject to his continuous service through that date. The reported $5.87 per-share figure equals the weighted average closing price for the ten trading days ending the day before the grant.
Lifevantage Corp director Judd Dayton received an award of 17,888 common shares on November 5, 2026, under the outside director compensation program. The reported $5.87 per share is the weighted average closing price for the 10 trading days ending the day before the grant. The shares vest in a single installment on November 5, 2027, subject to continuous service. His reported direct holdings following the award were 98,247 shares; a separate indirect holding of 749,325 shares is listed as held by Sudbury Capital Fund, LP.
LifeVantage Corporation reported fiscal 2027 first-quarter revenue of $37.1 million, down 22.0% from $47.6 million a year earlier. Revenue declined 22.2% in the Americas and 21.2% in Asia/Pacific & Europe. The company attributed the decline primarily to fewer active accounts and lower MindBody GLP-1 System sales, partly offset by LoveBiome sales. Total active accounts were 98,000 as of September 30, 2026, versus 121,000 a year earlier.
Gross profit was $28.0 million, or 75.4% of revenue, versus $37.8 million, or 79.5%; the company cited a $1.045 million MindBody inventory-obsolescence allowance and higher shipping and warehouse costs. GAAP net loss was $0.2 million, or $0.02 per diluted share, versus net income of $2.2 million, or $0.17 per diluted share. Adjusted EBITDA was $1.9 million versus $3.9 million, and adjusted diluted EPS was $0.05 versus $0.18. Operating cash flow was $0.5 million generated, compared with $2.3 million used; cash was $13.7 million at September 30, 2026, and no debt was outstanding. No shares were repurchased; $58.5 million remained under the $60 million repurchase program.
LifeVantage Corporation reported net revenue of $37.117 million for the quarter ended September 30, 2026, versus $47.561 million for the quarter ended September 30, 2025. It recorded a net loss of $196,000, compared with net income of $2.155 million in the prior-year quarter. Management attributed the revenue decline primarily to fewer active accounts and lower MindBody GLP-1 System sales.
Active accounts were 98,000 as of September 30, 2026, versus 121,000 as of September 30, 2025. Gross profit margin was 75.4%, compared with 79.5%; inventory obsolescence costs were $1.3 million. Net cash provided by operating activities was $533,000, versus $2.305 million used in the prior-year quarter. Cash and equivalents were $13.726 million as of September 30, 2026.
The board declared a $0.05-per-share quarterly dividend, paid September 15, 2026. A stock repurchase program authorizes up to $60.0 million through December 31, 2027; $58.5 million remained as of September 30, 2026, and no shares were purchased under it during the quarter. The board also approved a change in the fiscal year-end to December 31, effective December 31, 2026.
LifeVantage Corporation was the issuer for which The Capital Management Corporation reported beneficial ownership of 2,307,489 common shares, or 18.3%, as of September 30, 2026. It reported sole voting power over 2,284,489 shares and sole dispositive power over 2,307,489 shares, with no shared voting or dispositive power. Pamela C. Simms, identified as the corporation’s Compliance Officer, signed the report.